Syndax Pharmaceuticals (SNDX): Rethinking Valuation After Revumenib Gains Key Clinical Guideline Upgrade

Syndax Pharmaceuticals (SNDX) just caught Wall Street’s attention after a pivotal announcement. The company revealed that the National Comprehensive Cancer Network has upgraded its clinical guidelines to include revumenib as a recommended treatment for a specific form of relapsed or refractory acute myeloid leukemia. This decision is grounded in strong results from the AUGMENT-101 trial, with findings validated in a major medical journal. The news appears alongside Syndax’s submission of a supplemental New Drug Application for revumenib and the therapy’s recent FDA Priority Review designation, raising questions about how much of this upside the market already sees on the horizon.

Investors have had a bumpy ride with Syndax over the past year. The stock’s decline of 17% for the year contrasts with a notable 61% rally over the past 3 months, hinting at renewed optimism after a stretch of weaker sentiment. Other events, such as the company’s presentation at BioProcess International 2025, have added to the recent spotlight. However, this latest NCCN guideline update marks a shift in clinical credibility that could influence the valuation picture.

After the stock’s recent comeback, do investors have a new entry point here or is the current price simply catching up with the company’s growth prospects?

Most Popular Narrative: 59% Undervalued

The consensus among the most widely followed market observers is that Syndax Pharmaceuticals is trading well below its estimated fair value, with fresh guideline inclusion and expanding drug franchises playing a central role in this thesis.

Fixed operating expense base, together with expanding product sales and cash flow contributions from both franchises, is positioned to drive significant operating leverage. This boosts net margins and accelerates the pathway to profitability. Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues. These developments align with surging demand for innovative, targeted therapies and support sustained multi-year earnings momentum.

Want to know the roadmap behind this bold upside? One core ingredient transforms Syndax’s future from promise to profit, and the narrative leans heavily on ambitious pipeline expansion and a profit turnaround that rivals some tech valuations. Ever wondered what scale of growth or future margin is baked in? There is a surprising combination of revenue accelerators and aggressive profitability steps at play. Discover which projections tip the fair value so far above the current stock price.

Result: Fair Value of $36.55 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, setbacks in key drug approvals or stiffer than expected competition could quickly challenge the current growth outlook for Syndax Pharmaceuticals.

Find out about the key risks to this Syndax Pharmaceuticals narrative.

Another View: Industry Comparisons Tell a Different Story

While analysts see Syndax as deeply undervalued, a look at its price-to-sales ratio against the wider biotech industry paints a tougher picture. This highlights that the stock appears expensive on this metric. Can both views be right?

See what the numbers say about this price — find out in our valuation breakdown.

Stay updated when valuation signals shift by adding Syndax Pharmaceuticals to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Syndax Pharmaceuticals Narrative

If you want to dig deeper or think a different story is emerging from the numbers, take control and craft your own perspective in just a few minutes: Do it your way.

A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Syndax Pharmaceuticals.

Searching for Smart New Investment Ideas?

Broaden your portfolio with opportunities that most investors overlook. Let Simply Wall Street's handpicked lists help you target growth, innovation, and solid returns before others catch on.

• Tap into explosive tech trends by tracking companies on the move with AI penny stocks, positioned at the forefront of artificial intelligence.
• Secure reliable income streams by reviewing dividend stocks with yields > 3%, where yields above 3% reveal standout dividend payers built for stability.
• Seize tomorrow’s breakout potential by targeting undervalued stocks based on cash flows for hidden gems trading at attractive valuations based on future cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com